

March 20, 2018

The Honorable Paul Tonko U.S. House of Representatives Washington, DC 20515

The Honorable Ben Ray Lujan U.S. House of Representatives Washington, DC 20515

The Honorable Elise Stefanik U.S. House of Representatives Washington, DC 20515

The Honorable David McKinley U.S. House of Representatives Washington, DC 20515

Dear Representative Tonko, Representative Lujan, Representative Stefanik, and Representative McKinley:

I write to express the National Coalition on Health Care's (NCHC) support for HR 3692, the Addiction Treatment Access Improvement Act.

NCHC is a nonpartisan, nonprofit organization representing more than 80 participating organizations, including medical societies, businesses, unions, health care providers, faith-based associations, pension and health funds, insurers, and groups representing consumers, patients, women, minorities, and persons with disabilities. The Coalition is committed to advancing - through research and analysis, education, outreach, and informed advocacy – an affordable, high-value health care system for patients and consumers, payers, employers, and taxpayers.

Opioid Use Disorder (OUD) and other Substance Use Disorders (SUDs) are exacting an enormous toll in lives and in increased economic burden. The National Institute of Drug Abuse estimates that 64,000 Americans lost their lives to drug overdoses alone in 2016. According to the Altarum Institute, the combined economic costs of substance abuse since 2001 have exceeded \$1 trillion, inclusive of health spending as well as lost wages and productivity.

Yet as of today, the specialty behavioral health infrastructure and workforce is not large enough to successfully address this challenge. Prevention, screening, assessment, and treatment for substance use disorders, and other behavioral health conditions, must be fully integrated with the

1111 14TH STREET, NW, SUITE 900, WASHINGTON, DC 20005 | (202) 638-7151 | NCHC.ORG

hairman

Jack Lewin Principal and Founder Lewin and Associates LLC

President and CEO

Board of Directors

Liana Bailey-Crimmins
Chief Health Director,
CalPERS

Peter Begans Senior Vice President, Public and Government Affairs, SCAN Health Plan

Blair Childs Senior Vice President of Public Affairs, Premier Inc. Don Crane
President and CEC

Chris Dawe
Managing Director,
Evolent Health

David Dobbins
COO,
American Legacy Fou

Kevin Donnellan Executive Vice President & AARD The Honorable David Durenberge Former U.S. Senator from Minnesota

Michael Maccoby
President,
The Maccoby Group

Shawn Martin Senior Vice President, Advocacy, Practice Advancement, and Policy American Academy of Family Physicians

Margaret E. O'Kane President Damon Silvers
Director of Policy and Specia
Counsel,
AFL-CIO

Christine Simmon Senior Vice President of Policy & Strategic Alliances Association for Accessible Medicines

CEO,

Marshfield Clinic Health System

rest of health care – particularly primary care. To effectively combat this epidemic, the United States must mobilize the full range of health care professionals.

HR 3692 would make meaningful progress towards this goal. It makes permanent the broad buprenorphine prescribing authority for Nurse Practitioners and Physician Assistants that was enacted as part of the Comprehensive Addiction Recovery Act of 2016. This legislation further expands that authority to Certified Nurse Midwives, Clinical Nurse Specialists, and Certified Registered Nurse Anesthetists and eases restrictions on the number of patients that can be treated by qualified practitioners.

At a time when opioid use and substance use disorders seriously threaten the nation's health, we must bring all qualified health professionals fully into this fight. Please do not hesitate to contact NCHC's Policy Director Larry McNeely at lmcneely@nchc.org if you have questions regarding this letter or related issues.

Yours truly,

John Rother

President and CEO